Publication
MHY5535, a novel PPARα antagonist, sensitizes ovarian cancer stem cells to chemotherapy by disrupting fatty acid oxidation-dependent mitochondrial metabolism.
Min Joo Shin, Sang Gyun Noh, Seo Yul Lee, Hee Jin Jung, Seong-Jang Kim, Hae Young Chung, Hyung Ryong Moon, Jae Ho Kim
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieOct 1, 2026PMID 42585815doi:10.1016/j.biopha.2026.119842 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Ovarian cancer stem cells (CSCs) drive chemoresistance and tumor relapse through metabolic adaptability and enhanced mitochondrial function. Emerging evidence implicates peroxisome proliferator-activated receptor α (PPARα) as a critical regulator of CSC metabolism. Expression profiling and…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.